TransMedics delivered the kind of top-line quarter its skeptics were not positioned for. Adjusted earnings of $0.51 per share beat the $0.27 consensus by 88.9%, and revenue of $203.01 million topped the $181.81 million estimate by 11.7%. Revenue grew 41.1% year over year. Organic growth, which excludes the newly consolidated PAD Aviation, was still about 35%. That is a sharp acceleration from the 21% growth posted in both Q1 and Q2. Management raised full-year guidance again. The central tension is that the growth engine reignited while profitability did not follow: earnings still fell 22.7% year over year, and the margin outlook remains well below where it stood earlier in the year.

The quality of the beat deserves scrutiny, though it holds up better than the EPS decline suggests. On a GAAP basis, net income fell to $17.1 million, or $0.46 per share, from $24.3 million, or $0.66. Much of that gap sits below the operating line. Interest expense roughly doubled to $7.3 million as new finance-lease obligations hit the balance sheet. The company also swung from a $1.3 million tax benefit to a $7.0 million provision. Operating income actually rose 21% to $28.1 million. Operating margin compressed to 13.9% from 16.2% because operating expenses jumped to $90.5 million from $61.3 million. Research, development and clinical spending nearly doubled to $29.2 million as the company funded OCS Kidney, next-generation OCS and the ENHANCE trials. Reported gross margin slipped to 58.5% from 58.8%, but that figure masks a mix effect. Management said PAD dilutes gross margin by roughly 260 basis points. Excluding PAD, gross margin was 61.1%, and product gross margin improved to 79.2% from 77% in Q2.

The call showed demand broadening rather than leaning on a single driver. Product revenue growth accelerated to 29% from 16% in Q2. International revenue rose 82%. Liver and heart case volumes grew sequentially despite seasonality and a 6% decline in U.S. deceased donors, which suggests utilization gains are offsetting a weaker donor pool. Adjusted operating margin improved sequentially for a second straight quarter, to 14.2% from 13.6% in Q2 and 10.4% in Q1. Cash rose $20 million to $493 million. There were weaker spots, however:

• Service gross margin fell to 32.2% from about 35% in Q2, and management guided to further normalization in Q4.
• October flight activity was described as soft.

The guidance raise was real but measured. Excluding PAD, the range moved to $750–$760 million from $737–$757 million. The midpoint rose by less than the size of the Q3 revenue beat. Subtracting nine-month organic revenue from that range implies an organic fourth quarter roughly in line with, to modestly above, Q3. The full-year operating margin outlook was held at 12.5–14%. That range had already been cut from roughly 16% on the Q2 call. Management offered no 2027 margin commentary and did not reiterate its earlier target of a 30% operating margin by 2028.

The catalyst slate is the bull case's strongest asset, and its timing is the bears' best ammunition. The FDA approved IDEs for ENHANCE Heart Part B and DENOVO Lung, both using CHOPS as a control arm. ENHANCE Part A completed enrollment of 175 patients and received a 90-patient continued access protocol. In Europe, PAD won a multi-year logistics tender in Italy, and the company plans to launch its National OCS Program in Italy, the Netherlands and Belgium in the first half of 2027. Yet the clinical timetable keeps drifting:

• Trial-related revenue has been pushed from late Q4 2026 to Q1 2027.
• The CHOPS 510(k) slipped from the first half to the second half of 2027.
• OCS Kidney first-in-human experience is now slated for the second half of 2027.

On regulation, management said it sees no impediment to the business from the new CMS rule on organ procurement organizations.

Investor expectations entered the report subdued. Earnings Whispers sentiment remained negative but improved, rising from -0.42 to -0.31. Shares closed at $72.76 the day before the report, essentially unchanged (+0.6%) from the open after the August release. That flat reading hides a rough round trip. The stock peaked at $95.18 on August 21, then slid to $64.64 on October 30, and entered earnings 23.6% below that high. Price and AVWAP trend readings remain negative, while sequential-growth and momentum readings are neutral. In short, the market had already stripped out the summer optimism before this print.

The bottom line is that TransMedics answered the most pressing question, whether growth could reaccelerate, with an emphatic yes, backed by a revenue beat, broad-based volume gains and another guidance raise. What it did not resolve is the profitability trajectory. Margins are being held flat by heavy R&D spending, PAD mix and normalizing service margins, and the longer-term margin target has gone quiet. With key trial revenue and pipeline milestones sliding further into 2027, the stock's rebound depends on investors valuing the growth today while waiting longer for the margin and catalyst payoff.